Colony Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $4.17M | Sell |
55,632
-1,184
| -2% | -$91.1K | 0.06% | 235 |
|
|
2023
Q2 | $4.38M | Buy |
56,816
+123
| +0.2% | +$9.81K | 0.06% | 239 |
|
|
2023
Q1 | $4.7M | Sell |
56,693
-7,808
| -12% | -$647K | 0.07% | 228 |
|
|
2022
Q4 | $5.54M | Buy |
64,501
+2,125
| +3% | +$168K | 0.08% | 217 |
|
|
2022
Q3 | $3.85M | Sell |
62,376
-2,775
| -4% | -$175K | 0.07% | 241 |
|
|
2022
Q2 | $4.03M | Sell |
65,151
-23,135
| -26% | -$1.43M | 0.07% | 230 |
|
|
2022
Q1 | $5.25M | Buy |
88,286
+40,017
| +83% | +$2.56M | 0.08% | 216 |
|
|
2021
Q4 | $3.5M | Sell |
48,269
-37,597
| -44% | -$2.59M | 0.06% | 254 |
|
|
2021
Q3 | $6M | Buy |
85,866
+70,515
| +459% | +$4.95M | 0.12% | 157 |
|
|
2021
Q2 | $1.06M | Sell |
15,351
-45,630
| -75% | -$3.05M | 0.02% | 385 |
|
|
2021
Q1 | $3.94M | Buy |
60,981
+5,136
| +9% | +$331K | 0.08% | 203 |
|
|
2020
Q4 | $3.25M | Sell |
55,845
-3,437
| -6% | -$207K | 0.08% | 219 |
|
|
2020
Q3 | $3.75M | Buy |
59,282
+1,857
| +3% | +$129K | 0.1% | 184 |
|
|
2020
Q2 | $4.42M | Sell |
57,425
-3,652
| -6% | -$280K | 0.13% | 155 |
|
|
2020
Q1 | $4.57M | Sell |
61,077
-651
| -1% | -$45K | 0.15% | 149 |
|
|
2019
Q4 | $4.01M | Sell |
61,728
-4,808
| -7% | -$313K | 0.1% | 191 |
|
|
2019
Q3 | $4.22M | Buy |
66,536
+3,018
| +5% | +$197K | 0.13% | 175 |
|
|
2019
Q2 | $4.29M | Buy |
63,518
+59,217
| +1,377% | +$3.9M | 0.14% | 173 |
|
|
2019
Q1 | $280K | Buy |
+4,301
| New | +$286K | 0.01% | 527 |
|
|
2018
Q4 | – | Sell |
-4,202
| Closed | -$324K | – | 515 |
|
|
2018
Q3 | $324K | Buy |
4,202
+691
| +20% | +$52.2K | 0.02% | 393 |
|
|
2018
Q2 | $249K | Sell |
3,511
-375
| -10% | -$26.5K | 0.01% | 442 |
|
|
2018
Q1 | $293K | Buy |
3,886
+1,038
| +36% | +$82.5K | 0.02% | 404 |
|
|
2017
Q4 | $204K | Buy |
2,848
+125
| +5% | +$9.49K | 0.01% | 462 |
|
|
2017
Q3 | $221K | Sell |
2,723
-518
| -16% | -$39.6K | 0.02% | 412 |
|
|
2017
Q2 | $229K | Buy |
+3,241
| New | +$216K | 0.02% | 387 |
|
|
2017
Q1 | – | Sell |
-5,736
| Closed | -$411K | – | 276 |
|
|
2016
Q4 | $411K | Sell |
5,736
-848
| -13% | -$63K | 0.04% | 211 |
|
|
2016
Q3 | $521K | Buy |
6,584
+660
| +11% | +$53.6K | 0.06% | 182 |
|
|
2016
Q2 | $494K | Buy |
5,924
+1,555
| +36% | +$138K | 0.05% | 173 |
|
|
2016
Q1 | $401K | Sell |
4,369
-9,907
| -69% | -$893K | 0.05% | 180 |
|
|
2015
Q4 | $1.45M | Sell |
14,276
-57
| -0.4% | -$5.93K | 0.13% | 152 |
|
|
2015
Q3 | $1.41M | Buy |
14,333
+2,293
| +19% | +$255K | 0.16% | 134 |
|
|
2015
Q2 | $1.41M | Buy |
12,040
+8,164
| +211% | +$892K | 0.15% | 130 |
|
|
2015
Q1 | $380K | Sell |
3,876
-3,502
| -47% | -$356K | 0.04% | 235 |
|
|
2014
Q4 | $695K | Buy |
7,378
+3,020
| +69% | +$312K | 0.07% | 210 |
|
|
2014
Q3 | $464K | Sell |
4,358
-611
| -12% | -$59.8K | 0.05% | 246 |
|
|
2014
Q2 | $412K | Buy |
4,969
+786
| +19% | +$61.2K | 0.06% | 171 |
|
|
2014
Q1 | $296K | Buy |
4,183
+240
| +6% | +$18.8K | 0.04% | 191 |
|
|
2013
Q4 | $296K | Buy |
+3,943
| New | +$275K | 0.04% | 183 |
|
Other funds holding GILD
Colony Group's GILD Position: Q3 2023 in Review
Colony Group reduced its Gilead Sciences (GILD) stake by 2.1% in Q3 2023, selling an estimated $91.1K and leaving 55,632 shares worth $4.17M. The position accounts for 0.06% of the portfolio, ranked #235.
Colony Group first reported a position in GILD in Q4 2013 and has held it in 38 quarters since. The position peaked at $6M in Q3 2021. 1,682 funds tracked by Wall St. Rank hold GILD as of Q3 2023.
- Colony Group held 55,632 shares of Gilead Sciences worth $4.17M as of Q3 2023.
- Colony Group sold 1,184 Gilead Sciences shares in Q3 2023, an estimated $91.1K.
- Gilead Sciences made up 0.06% of Colony Group's portfolio in Q3 2023, its #235 holding.
- Colony Group first reported a position in Gilead Sciences in Q4 2013 and has held it in 38 quarters since.
- Colony Group's Gilead Sciences position peaked at $6M in Q3 2021.
- 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.
Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.